[go: up one dir, main page]

DK3256107T3 - Farmaceutisk formulering af racecadotril - Google Patents

Farmaceutisk formulering af racecadotril Download PDF

Info

Publication number
DK3256107T3
DK3256107T3 DK15819831.7T DK15819831T DK3256107T3 DK 3256107 T3 DK3256107 T3 DK 3256107T3 DK 15819831 T DK15819831 T DK 15819831T DK 3256107 T3 DK3256107 T3 DK 3256107T3
Authority
DK
Denmark
Prior art keywords
racecadotril
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
DK15819831.7T
Other languages
English (en)
Inventor
Piero Poli
Alessandro Fiorino
Tommaso Roberto Piazzolla
Original Assignee
Rivopharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rivopharm Sa filed Critical Rivopharm Sa
Application granted granted Critical
Publication of DK3256107T3 publication Critical patent/DK3256107T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK15819831.7T 2015-02-09 2015-12-23 Farmaceutisk formulering af racecadotril DK3256107T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITTO20150086 2015-02-09
PCT/EP2015/081187 WO2016128098A1 (en) 2015-02-09 2015-12-23 Pharmaceutical formulation of racecadotril

Publications (1)

Publication Number Publication Date
DK3256107T3 true DK3256107T3 (da) 2020-08-31

Family

ID=53002778

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15819831.7T DK3256107T3 (da) 2015-02-09 2015-12-23 Farmaceutisk formulering af racecadotril

Country Status (19)

Country Link
US (1) US10188607B2 (da)
EP (1) EP3256107B1 (da)
JP (1) JP6851973B2 (da)
CN (1) CN107438431B (da)
AU (1) AU2015382526B2 (da)
BR (1) BR112017016997A2 (da)
CA (1) CA2975930A1 (da)
DK (1) DK3256107T3 (da)
EA (1) EA035038B1 (da)
ES (1) ES2822992T3 (da)
GE (1) GEP20197006B (da)
HU (1) HUE051692T2 (da)
IL (1) IL253788A0 (da)
LT (1) LT3256107T (da)
PL (1) PL3256107T3 (da)
PT (1) PT3256107T (da)
SG (1) SG11201706431SA (da)
WO (1) WO2016128098A1 (da)
ZA (1) ZA201705329B (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2026905B1 (en) 2020-11-16 2022-06-30 Pharmamatch B V Pharmaceutical granulate formulation and method for the preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0914822A4 (en) * 1996-03-14 2002-08-07 Bayer Ag PREPARATION OF ECADOTRIL WITH FAST MICRODISPERSION AND RELEASE
GB0015490D0 (en) * 2000-06-23 2000-08-16 Smithkline Beecham Lab Novel formulations
FR2900823B1 (fr) * 2006-05-15 2009-02-13 Bioprojet Soc Civ Ile Nouvelle forme d'administration du racecadotril.
CA2694516A1 (en) * 2007-07-31 2009-02-05 Cargill, Incorporated Direct compressible dextrose
CN102166197B (zh) * 2011-04-25 2012-09-05 四川百利药业有限责任公司 消旋卡多曲颗粒及其生产工艺
CN102327234B (zh) * 2011-09-28 2017-04-12 海南康芝药业股份有限公司 一种消旋卡多曲干混悬剂
CN104224724A (zh) * 2013-06-08 2014-12-24 北京韩美药品有限公司 一种消旋卡多曲颗粒剂及其制备工艺
EP2918268A1 (en) * 2014-03-10 2015-09-16 Galenicum Health S.L. Pharmaceutical compositions comprising an active agent

Also Published As

Publication number Publication date
CN107438431A (zh) 2017-12-05
EA035038B1 (ru) 2020-04-21
IL253788A0 (en) 2017-09-28
AU2015382526A1 (en) 2017-08-24
CN107438431B (zh) 2020-12-15
PT3256107T (pt) 2020-09-23
EP3256107B1 (en) 2020-08-12
LT3256107T (lt) 2020-09-25
ES2822992T3 (es) 2021-05-05
HUE051692T2 (hu) 2021-03-29
JP6851973B2 (ja) 2021-03-31
CA2975930A1 (en) 2016-08-18
ZA201705329B (en) 2019-06-26
AU2015382526B2 (en) 2020-09-10
JP2018505208A (ja) 2018-02-22
GEP20197006B (en) 2019-07-25
BR112017016997A2 (pt) 2018-04-10
EA201791794A1 (ru) 2017-12-29
EP3256107A1 (en) 2017-12-20
SG11201706431SA (en) 2017-09-28
US10188607B2 (en) 2019-01-29
WO2016128098A1 (en) 2016-08-18
US20180028448A1 (en) 2018-02-01
PL3256107T3 (pl) 2021-03-22

Similar Documents

Publication Publication Date Title
DK3256138T3 (da) Farmaceutiske sammensætninger omfattende meloxicam
DK3244948T3 (da) Bestemmelse af medikamentdosis
DK3509581T3 (da) Formuleringer af (r)-2-amino-3-phenylpropylcarbamat
EP3352757C0 (en) ADMINISTRATION OF DEUTERIUM-MODIFIED CFTR POTENTIATION AGENTS
HUE047477T2 (hu) Palbociclib szilárd dózisformái
DK3529248T3 (da) Farmaceutiske sammensætninger
EP3513809A4 (en) MEDICAL COMPOSITION
PL4070788T3 (pl) Formulacje farmaceutyczne
DK3116491T3 (da) Farmaceutiske sammensætninger af terapeutisk aktive forbindelser
EP3364944C0 (en) PHARMACEUTICAL COMPOSITIONS OF IL-2
LT3362049T (lt) Kamptotecino farmacinių kompozicijų stabilizavimas
MA42303A (fr) Formulations pharmaceutiques
DK3634377T3 (da) Farmaceutisk formulering
DK3474822T3 (da) Formuleringer af brincidofovir
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation
DK3310331T3 (da) Injicerbare farmaceutiske formuleringer af lefamulin
DK3400017T3 (da) Kontinuerlig kompleksering af aktive farmaceutiske ingredienser
EP3383371A4 (en) PHARMACEUTICAL FORMULATION
DK3678644T3 (da) Formuleringer af copanlisib
DK3280447T3 (da) Farmaceutiske formuleringer
IL258630A (en) Formulation of l-ornithine phenylacetate
EP3337463A4 (en) PHARMACEUTICAL FORMULATIONS
DK3601277T3 (da) Farmaceutisk formulering
MA43166A (fr) Formulation de fviii